Nicholas J. Vogelzang, MD, FASCO, FACP is part of Comprehensive Cancer’s board certified and award-winning medical oncologist team that provides world-class cancer care in a supportive and caring environment.
Dr. Nicholas J. Vogelzang received his medical degree from the University of Illinois in Chicago. He completed his internship and residency in internal medicine at Rush Presbyterian St. Luke’s Medical Center in Chicago and he completed his fellowship in medical oncology at the University of Minnesota in Minneapolis.
AREAS OF SPECIAL INTEREST
Genitourinary Malignancies (prostate, kidney, bladder and testicular cancer) and Mesothelioma
Dr. Vogelzang is a renowned medical oncologist and cancer researcher who has authored/coauthored numerous peer-reviewed articles, book chapters and abstracts. He was the lead editor of the Comprehensive Textbook of Genitourinary Oncology from 1994-2008. Dr. Vogelzang joined Comprehensive Cancer Centers as a medical oncologist in 2009. He serves as the Associate chair of the Genitourinary (GU) Committee for US Oncology Research and Vice Chair of GU Committee SWOG, a worldwide network of researchers that design and conduct cancer clinical trials. Dr. Vogelzang serves as Clinical Professor of Medicine at University of Nevada School of Medicine as well as Clinical Professor at UNLV School of Medicine. He is also Associate Editor of Kidney Cancer Journal and Clinical Genitourinary Cancer.
Prior to joining Comprehensive, he served as Director of Nevada Cancer Institute from 2004 to 2009. From 1999 to 2003, Dr. Vogelzang was Fred C. Buffett Professor and Director of the University of Chicago Cancer Research Center and faculty member from 1982 to 2003.
Dr. Vogelzang leads and participates in multiple clinical trials in genitourinary malignancies, phase1 and mesothelioma focusing on new therapies for patients with metastatic kidney, bladder and prostate cancer. He has lead research in Las Vegas for two FDA-approved prostate cancer treatments – Provenge and Xofigo. In 2014, Nature published the international phase 1 teams research on an anti-PD-L1 treatment called atezolizumab (commercially known as TECENTRIQ) for metastatic bladder cancer. The FDA approved the treatment in May 2016.
Dr. Vogelzang was named Distinguished Physician of the year by the Nevada State Medical Association and received the Laureate award from the American College of Physicians in Nevada in 2013. He has been named America’s Top Doctor by Castle Connolly, Top Doctor by U.S. News & World Report, Best Physicians in Southern Nevada as chosen by their peers by Desert Companion, Everyday Hero from the American Red Cross Southern Nevada, Health Care Headliner by Vegas Inc. and Medical Marvels by Nevada Business Magazine. He was also awarded the Gold Certificate of Excellence by National Cancer Institute and the Inspired Excellence in Health Care Award by Las Vegas HEALS.
Dr. Vogelzang has been featured in several national and local media outlets in relation to his cancer research work including The New York Times, USA Today, New England Journal of Medicine, Nature, 60 Minutes and the Las Vegas Review-Journal.
Dr. Vogelzang has served on numerous committees for the American Society of Clinical Oncology (ASCO), as well as on its board of directors for three years.
MEMBERSHIPS IN PROFESSIONAL ASSOCIATIONS
American Association of Cancer Research
American College of Physicians – Fellow
American Society of Clinical Oncology – Fellow
American Urological Association
Clark County Medical Society
European Society for Medical Oncology
International Association for the Study of Lung Cancer
Kidney Cancer Association
Nevada Oncology Society
Society of Urologic Oncology
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology., Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG., J Clin Oncol. 2012 Jan 1;30(1):88-109. Epub 2011 Dec 5. PMID: 22147736 [PubMed – indexed for MEDLINE] Read more.
Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy., Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J., J Clin Oncol. 2011 Jun 10;29(17):2432-8. Epub 2011 May 9. Review., PMID: 21555688 [PubMed – indexed for MEDLINE] Read more.
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study., Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM., J Clin Oncol. 2011 May 20;29(15):2040-5. Epub 2011 Apr 18. PMID: 21502546 [PubMed – indexed for MEDLINE] Read more.
Secondary hormonal manipulations in the treatment of castration refractory prostate cancer., Agarwal N, Vogelzang NJ., BJU Int. 2011 Jul;108(2):227-8. doi: 10.1111/j.1464-410X.2010.09970.x. Epub 2010 Nov 24. No abstract available. PMID: 21410863 [PubMed – indexed for MEDLINE] Read more.
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy., Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J., Lancet Oncol. 2011 Mar;12(3):211-4. No abstract available. PMID: 21376284 [PubMed – indexed for MEDLINE] Read more.
You can find more information about Dr. Vogelzang on Wikipedia.